Effect of High Dose Rosuvastatin Loading before Primary Percutaneous Coronary Intervention on Infarct Size in Patients with ST-Segment Elevation Myocardial Infarction

Ji Won Kim, MD, Kyeong Ho Yun, MD, Eun Kyoung Kim, MD, Yong Cheol Kim, MD, Dai-Yeol Joe, MD, Jum Suk Ko, MD, Sang Jae Rhee, MD, Eun Mi Lee, MD, Nam Jin Yoo, MD, Nam-Ho Kim, MD, Seok Kyu Oh, MD, and Jin-Won Jeong, MD
Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital, Iksan, Korea

Background and Objectives: High dose rosuvastatin loading before percutaneous coronary interventions (PCI) reduces the myocardial damage and the incidence of adverse cardiac events in patients with stable angina and acute coronary syndrome. However, no studies are present yet about rosuvastatin loading in patients with ST-segment elevation myocardial infarction (STEMI) in a primary PCI setting.

Subjects and Methods: A total of 475 patients who underwent primary PCI for STEMI were studied. The study population was divided into two groups with 208 patients in the statin group=40 mg rosuvastatin loading before primary PCI and 267 patients in the control group= no statin pretreatment. At median 3 days after PCI a single-photon emission computed tomography (SPECT) was performed with technetium 99m tetrofosmin For this study were compared infarct size, corrected Thrombolysis in Myocardial Infarction (TIMI) frame count and the myocardial blush grade (MBG) between the both groups.

Results: Baseline clinical and procedural characteristics were similar between the groups. Infarct size, as assessed by SPECT, was significantly smaller (19.0±15.9% vs. 22.9±16.5%, p=0.009) in the statin group than in the control group. Patients of the statin group showed a lower corrected TIMI frame count (28.2±19.3 vs. 32.6±21.4, p=0.020), and higher MBG (2.49±0.76 vs. 2.23±0.96, p=0.001) than the patients of the control group. The multivariate analysis revealed that rosuvastatin loading (odds ratio (OR) 0.61), pain to balloon time (OR 2.05), anterior myocardial infarction (OR 3.89) and final the MBG (OR 2.93) were independent predictors of a large infarct size.

Conclusion: A high dose rosuvastatin loading before the primary PCI reduced the infarct size by microvascular myocardial perfusion improvement. (Korean Circ J 2014;44(2):76-81)

KEY WORDS: Angioplasty; Myocardial infarction; Stents; Hydroxymethylglutaryl-CoA Reductase inhibitors.
of High-Dose AtorvaSTATIN Loading Before Primary PCI in ST-Elevation Myocardial Infarction (STATIN STEMI) trial demonstrated a 80 mg atorvastatin loading improved the coronary flow and perfusion after primary PCI. However, the number of STATIN STEMI participants was too small to draw a definite conclusion and further large trials are required to confirm the effect of statin loading in a primary PCI setting. Therefore, a retrospective study was designed to investigate the effects of high dose rosuvastatin loading before primary PCI on infarct size in patients with STEMI.

Subjects and Methods

Study population

For this study a single center STEMI and a primary PCI cohort were analyzed from January 2008 to December 2012. During the study period, 516 consecutive patients underwent primary PCI for STEMI. A total of 24 patients were excluded because of current treatment with statins, 8 patients were excluded because they died before they underwent the technetium 99m tetrofosmin single-photon emission computed tomography (SPECT) study, 8 patients were excluded because of SPECT refusal and 1 patient was excluded because of an inadequate image. Therefore 475 patients were eligible patients; of these, 208 patients received 40 mg rosuvastatin loading before primary PCI (statin group) and 267 patients didn’t receive any statin pretreatment (control group). Rosuvastatin loading was performed in the emergency room at the on-call physician’s discretion. All patients provided informed consent for processing their anonymous data according to a protocol approved by the Institutional Review Board of Wonkwang University Hospital (WKUHIRB-201310-HRE-021).

Percutaneous coronary intervention

Before the procedure aspirin (300 mg/day) and clopidogrel (300 mg/day) were loaded in all patients. An intravenous bolus of 5000 U of unfractionated heparin was given heparin boluses were given to maintain activated clotting time >300 seconds during the procedure additionally. The coronary angiography and the stent implantation were performed using standard interventional techniques. Platelet glycoprotein IIb/IIIa inhibitors were administered according to the operator’s preference. After the procedure aspirin (100 mg/day), clopidogrel (75 mg/day) and statins were prescribed to all patients.

Data collection and analyses

Pre- and post-PCI angiograms were reviewed. The Thrombolysis in Myocardial Infarction (TIMI) flow grade before and after PCI, the corrected TIMI frame count (cTFC) and the myocardial blush grade (MBG) were analyzed by 2 experienced blinded observers as described previously. Creatine kinase myocardial band isoenzyme (CK-MB) isoenzyme and troponin T were measured before primary PCI and 8, 24 and 48 hours after. Peak concentrations were identified and the area under time-concentration curve was estimated from cardiac biomarker levels measured at individual time-points. Troponin T was measured quantitatively (Elecsys Troponin T assay, Roche Diagnostics, Indianapolis, IN, USA) with a detection threshold of 0.003 ng/mL.

To evaluate major adverse cardiac events (MACE) such as death, new myocardial infarction and target vessel revascularization a clinical follow-up was performed on day 30 with all patients.

Single-photon emission computed tomography and left ventricular function assessment

Single-photon emission computed tomography imaging with technetium 99m tetrofosmin was performed by a standardized technique. After injection of adenosine, 370 MBq of technetium 99m tetrofosmin was injected intravenously and stress myocardial images were obtained. After 4 hours, another 1110 MBq of technetium 99m tetrofosmin was administered intravenously and the resting myocardial images were obtained. The SPECT images were acquired on a dual–headed gamma camera (Vertex 60, Philips ADAC, Milpitas, CA, USA) equipped with high-resolution collimators. Myocardial perfusion defects (infarct size) were quantified and expressed as a percentage involvement of the left ventricle. The patients underwent SPECT imaging in a median of 3 days (interquartile range, 2–4 days) after PCI.

Study end points

The primary end point was the myocardial infarct size as assessed by SPECT. The secondary end points included 1) TIMI flow grade, cTFC, MBG after PCI, 2) infarct size assessed by serial cardiac biomarker measurement, and 3) 30-day MACE.

Statistical analysis

Based upon preliminary data of the Wonkwang Medical Center, the infarct size of the control group was expected to be 20% (standard deviation 15%). The sample size was selected to demonstrate a reduction in the infarct size from 20% in the control group to 15% in the statin group. A minimal sample size of 178 patients in each group would provide 80% power with two-sided alpha of 0.05.

All measurements were represented as mean±standard deviation or absolute number (percentage). Inter-group analysis was performed using independent t-test and χ² test, which were conducted using Statistical Package for the Social Sciences (SPSS) 19.0 for Windows (SPSS Inc., Chicago, IL, USA). To compare the change of cardiac biomarkers before and after PCI, the paired t-test was used. A multivariable logistic regression model was constructed to predict large infarct size (greater than median value, >18%). According to the
### Table 1. Baseline clinical characteristics

|                        | Control group (n=267) | Statin group (n=213) | p     |
|------------------------|-----------------------|----------------------|-------|
| Age (years)            | 60.8±13.2             | 62.2±12.9            | 0.249 |
| Male (%)               | 77.5 (207)            | 73.2 (156)           | 0.286 |
| Hypertension (%)       | 50.9 (136)            | 41.8 (89)            | 0.053 |
| Diabetes (%)           | 25.5 (68)             | 20.2 (43)            | 0.192 |
| Current smoker (%)     | 46.8 (125)            | 50.2 (107)           | 0.464 |
| Anterior infarction (%)| 41.6 (111)            | 47.9 (102)           | 0.195 |
| Killip class ≥2 (%)    | 12.4 (33)             | 8.9 (19)             | 0.241 |
| Door-to-balloon time (minutes) | 92.0±113.0          | 87.0±132.0           | 0.599 |
| Pain-to-balloon time (minutes) | 340.0±325.0        | 318.0±298.0          | 0.437 |

**Baseline laboratory findings**

|                        | Control group (n=267) | Statin group (n=213) | p     |
|------------------------|-----------------------|----------------------|-------|
| WBC (μL)               | 11338.4±2920.5        | 10896.2±3310.8       | 0.121 |
| Serum creatinine (mg/dL)| 1.01±0.30             | 0.97±0.33            | 0.175 |
| CK-MB (IU/L)           | 56.1±85.7             | 64.4±77.8            | 0.201 |
| Troponin T (mg/mL)     | 0.65±1.54             | 0.50±1.17            | 0.248 |
| Total cholesterol (mg/dL)| 196.8±48.8         | 194.8±37.9           | 0.601 |
| Triglyceride (mg/dL)   | 159.3±136.3           | 160.2±132.2          | 0.941 |
| HDL-C (mg/dL)          | 41.6±10.5             | 42.1±11.0            | 0.620 |
| LDL-C (mg/dL)          | 118.7±36.8            | 117.0±34.4           | 0.606 |

WBC: white blood cell, CK-MB: creatine kinase myocardial band isoenzyme, HDL-C: high density lipoprotein-cholesterol, LDL-C: low density lipoprotein-cholesterol

### Table 2. Coronary angiographic and procedural characteristics

|                        | Control group (n=267) | Statin group (n=213) | p     |
|------------------------|-----------------------|----------------------|-------|
| Culprit lesion (%)     |                       |                      | 0.241 |
| Left main              | 0.4 (1)               | 0.5 (1)              |       |
| Left anterior descending| 41.2 (110)           | 47.4 (101)           |       |
| Left circumflex        | 15.0 (40)             | 17.8 (38)            |       |
| Right coronary artery  | 43.4 (116)            | 34.3 (73)            |       |
| Multivessel disease (%)| 41.9 (112)            | 40.4 (86)            | 0.780 |
| Use of GPI (%)         | 54.7 (146)            | 49.3 (105)           | 0.270 |
| Type of PCI (%)        |                       |                      | 0.436 |
| Balloon only           | 0.4 (1)               | 0.9 (2)              |       |
| Stent                  | 99.6 (266)            | 99.1 (211)           |       |
| Multivessel PCI (%)    | 11.2 (30)             | 10.3 (22)            | 0.770 |
| Type of stent (%)      |                       |                      |       |
| Sirolimus eluting stent| 10.1 (27)             | 8.0 (17)             | 0.525 |
| Paclitaxel eluting stent| 11.6 (31)            | 11.7 (25)            | 1.000 |
| Zotarolimus eluting stent| 34.8 (93)           | 36.2 (77)            | 0.774 |
| Everolimus eluting stent| 31.5 (84)            | 23.5 (50)            | 0.065 |
| Stent number per patient| 1.4±0.7               | 1.3±0.5               | 0.028 |
| Stent diameter (mm)    | 3.2±0.3               | 3.2±0.3               | 0.727 |
| Total stent length (mm)| 37.5±19.7             | 35.0±16.3            | 0.144 |
| Maximal pressure (atm) | 15.3±3.3              | 15.9±3.3             | 0.063 |
| Procedural complications (%)* | 14.6 (39)       | 15.0 (32)            | 0.898 |

*Procedural complications included abrupt vessel closure, slow/no reflow, distal embolization, side branch occlusion, and major dissection during primary percutaneous coronary intervention. GPI: glycoprotein IIb/IIIa inhibitor, PCI: percutaneous coronary intervention
significant univariate analysis following variables were selected and inserted into the logistic regression analysis: rosvastatin loading, pain to balloon time, anterior infarction, angiographic slow flow and final MBG. Statistical significance was set at p<0.05.

Results

Baseline characteristics

The baseline clinical characteristics of the patients in the control and statin groups are shown in Table 1. The risk factors, door-to-balloon time and the baseline cardiac biomarker levels were similar between the groups. Most of all patients received drug-eluting stents and over 70% of the patients received second generation drug-eluting stents (Table 2). Angiographic and procedural characteristics were similar between the groups, but in the control group a greater number of stents was used than in the statin group (1.4±0.7 vs. 1.3±0.5, p=0.028).

Angiographic and biochemical outcomes

Angiographic no reflow and final TIMI flow grade <3 occurred at a similar rate in both groups (Table 3). The final cTFC was lower (28.2±19.3 vs. 32.6±21.4, p=0.020) and the final MBG was higher in the statin group (2.49±0.76 vs. 2.23±0.96, p=0.001).

All single time-points after PCI (8, 24, and 48 hours) and peak level of CK-MB and troponin T were lower in the statin group (Fig. 1). The statin group showed significantly lower cumulative CK-MB levels (367.9±297.3 IU/L vs. 483.5±340.4 IU/L, p<0.001) and cumulative troponin T levels (13.03±11.29 ng/mL vs. 16.53±13.04 ng/mL, p=0.005) than the control group.

Infarct size measured by single-photon emission computed tomography

The median infarct size was 18.0% (interquartile range, 7.0–32.8%). There was no difference in the time from PCI to SPECT between the groups (Table 3). The statin group revealed a significant smaller infarct size than the control group (19.0±15.9% vs. 22.9±16.5%, p=0.009). However, the left ventricular ejection fraction was similar between both groups.

Multivariate analysis revealed that rosvastatin loading (odds ratio (OR)=0.61; 95% confidence interval (CI)=0.41–0.91; p=0.015),

Table 3. Radionuclide imaging, angiographic, and clinical outcomes

|                      | Control group (n=267) | Statin group (n=213) | p     |
|----------------------|-----------------------|----------------------|-------|
| Follow-up time (days)| 3.8±3.1               | 3.8±3.6              | 0.886 |
| Infarct size (%)     | 22.9±16.5             | 19.0±15.9            | 0.009 |
| Ejection fraction (%)| 51.1±11.5             | 52.4±12.3            | 0.228 |
| Angiographic outcomes|                      |                      |       |
| Angiographic no reflow (%) | 6.7 (18)    | 8.0 (17)             | 0.602 |
| Baseline TIMI flow grade 0/1 (%) | 80.1 (214) | 77.9 (166)           | 0.573 |
| Final TIMI flow grade <3 (%) | 18.4 (49)  | 16.9 (36)            | 0.719 |
| Baseline corrected TIMI frame count | 166.1±65.2 | 162.2±68.6           | 0.553 |
| Final corrected TIMI frame count | 32.6±21.4 | 28.2±19.3            | 0.020 |
| Baseline TIMI blush grade | 0.58±1.14 | 0.60±1.10            | 0.904 |
| Final TIMI blush grade | 2.23±0.96 | 2.49±0.76            | 0.001 |
| 30-day clinical outcomes (%)|           |                      |       |
| All cause death      | 1.1 (3)               | 0.0 (0)              | 0.121 |
| New myocardial infarction | 0.4 (1)  | 0.0 (0)              | 0.371 |
| Target lesion revascularization | 0.4 (1) | 0.0 (0)              | 0.371 |
| Total events         | 1.5 (4)               | 0.0 (0)              | 0.073 |

SPECT: single-photon emission computed tomography, TIMI: Thrombolysis in Myocardial Infarction

Fig. 1. Time-concentration curve of creatine kinase myocardial band isoenzyme (CK-MB).
High Dose Statin Loading in STEMI

http://dx.doi.org/10.4070/kcj.2014.44.2.76

pain to balloon time >210 minutes (OR=2.03; 95% CI=1.41–2.92; p<0.001), anterior infarction (OR=3.89; 95% CI=2.56–5.91; p<0.001) and MBG <3 (OR=2.93; 95% CI=1.92–4.48; p<0.001) were independent predictors of the large (>18%) infarct size (Table 4).

30-day clinical outcomes

The incidences of MACE at day 30 were not significantly different between the groups (1.5% vs. 0%, p=0.073) (Table 3). No serious side effects were detected associated with rosuvastatin loading.

Discussion

In the present study it was shown the loading of 40 mg rosuvastatin before primary PCI is associated with a smaller infarct size which is measured by SPECT and lower levels of cardiac biomarkers. An improved coronary microcirculation was assessed by cTFC and MBG and may be attributable to the beneficial outcomes in the statin group.

High dose statin loading therapy before PCI can reduce the incidence of periprocedural MI and improve the outcomes in patients with ACS also. The ARMYDA-ACS trial was the first randomized study to assess the efficacy of high dose statin loading therapy before PCI in patients with ACS.41 As results of this trial an 80 mg atorvastatin loading 12 hours before PCI was indicated to reduce the postprocedural biomarker elevation and the 30-day MACE. Previously the authors performed a similar randomized study with 40 mg rosuvastatin. In this study the statin loading administered approximately 16 hours before PCI reduced the risk of periprocedural MI and 30-day MACE by 53% and 63%, respectively compared to the pretreatment without statin.42 However, the data of high dose statin loading in patients with STEMI were limited and not promising.

A chronic statin pretreatment before PCI reduced the length of hospital stay and the 30-day mortality and was an independent predictor of mortality in patients with MI in several non-randomized registries.43,44 However, prospective, randomized studies didn’t show a benefit of statin loading therapy in patients with STEMI. The 30-day and 9-month MACE were not reduced in the STATIN STEMI trial if 80 mg atorvastatin where loaded before the primary PCI.7 Nevertheless, the efficacy of statin loading therapy should not be based on the results of this study only because the incidence of clinical events was lower than originally hypothesized and the sample size was insufficient. In this study rather was identified a significant lower cTFC and higher MBG. Thus, possibly via beneficial effects on microvascular function the statin loading therapy might improve coronary blood flow after PCI. A similar finding was also observed in the present study. Hahn et al.44 demonstrated that 80 mg atorvastatin loading before primary PCI didn’t reduce the infarct size which was measured by SPECT or 6-month MACE. They also reported no improvement of MBG and cTFC after atorvastatin loading before the primary PCI compared with the control group. Liu et al.47 recently reported that 80 mg atorvastatin loading followed by 40 mg atorvastatin therapy could reduce the inflammatory response and improve the ejection fraction in patients with STEMI. The present observational study revealed a reduced infarct size, cardiac biomarker elevation and improved cTFC and MBG after 40 mg rosuvastatin loading, but the ejection fraction was not improved. This might be attributable to the heterogeneity of the study population and the small sample size in each study group.

Both atorvastatin and rosuvastatin are potent synthetic statins and commonly prescribed in patients with coronary artery diseases. They also have pleiotropic effects which encompass the non-lipid mechanisms which are responsible for the modification of endothelial function, inflammatory responses, plaque stability and thrombus formation.48 Acute effects of statin loading on MI may contribute to

### Table 4. Univariate and multivariate analysis for the prediction of >18% (median) infarct size

|                     | Univariate analysis | Multivariate analysis |
|---------------------|---------------------|-----------------------|
|                     | OR 95% CI  p        | OR 95% CI  p          |
| Rosuvastatin loading| 0.66 0.46–0.95 0.026| 0.61 0.41–0.91 0.015   |
| Door-to-balloon time >90 minutes | 1.34 0.86–2.08 0.204 |                   |
| Pain-to-balloon time >210 minutes | 2.03 1.41–2.92 <0.001 | 2.05 1.38–3.05 <0.001 |
| Use of GPI          | 0.74 0.52–1.06 0.098 |                       |
| Multivessel disease | 1.26 0.88–1.82 0.210 |                       |
| Anterior infarction | 2.80 1.93–4.06 <0.001| 3.89 2.56–5.91 <0.001 |
| Multivessel intervention | 1.38 0.77–2.46 0.282 |       |
| Angiographic slow flow | 3.20 1.47–6.99 0.003 | 2.22 0.95–5.20 0.066 |
| Corrected TIMI frame count <28 | 1.14 0.79–1.64 0.488 |       |
| TIMI blush grade <3 | 2.57 1.77–3.74 <0.001| 2.93 1.92–4.48 <0.001 |

OR: odds ratio, CI: confidence interval, GPI: glycoprotein IIb/IIIa inhibitor, TIMI: Thrombolysis in Myocardial Infarction
the plaque stability. Lee et al. reported the presence of functionally active 3-hydroxy-3-methylglutaryl-coenzyme A reductase in coronary atherosclerotic plaque. Statins may penetrate atherosclerotic lesions and suppress active plaque inflammation by binding of lesion 3-hydroxy-3-methylglutaryl-coenzyme A reductase. It has been shown that rosuvastatin forms the largest number of bonds with 3-hydroxy-3-methylglutaryl-coenzyme A reductase which leads subsequently to a superior efficacy. However, this hypothesis requires further confirmation. Therefore a large prospective study is needed to confirm the effect of statin loading in patients with STEMI.

The presented study has several limitations. Presumably due to a biochemical stunning of the myocardium which limits an isotope uptake the infarct size is often overestimated in the early SPECT imaging between 18 and 48 hours. Therefore, the size of perfusion defect in this study did not reflect the true infarct size. However, the timing of SPECT imaging was similar in both groups (3.8±3.1 days vs. 3.8±3.6 days, p=0.886) and the assessment of statin loading effects were carried out under similar conditions. The study was not randomized and the sample size was small. The effects of statin loading on clinical outcomes could not be accurately determined, however, conclusions could be drawn on the benefits on surrogate markers. Furthermore, the outcomes according to the kind of statins or dose of statins and the exact duration of the therapy were not identified.

In conclusion, a high dose rosuvastatin loading before primary PCI was associated with a reduced infarct size by an improved microvascular myocardial perfusion.

References

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
4. Hong YJ, Jeong MH, Lim JH, et al. The prognostic significance of statin therapy according to the level of C-reactive protein in acute myocardial infarction patients who underwent percutaneous coronary intervention. Korean Circ J 2003;33:891-900.
5. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009;373:1175-82.
6. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007;49:1272-8.
7. Yun KH, Jeong MH, Oh SK, et al. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol 2009;137:246-51.
8. Briguori C, Visconti G, Foracchia A, et al. Novel approaches for preventing or limiting events (Naples II trial): impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 2009;54:2157-63.
9. Yun KH, Oh SK, Rihee SJ, Yoo NJ, Kim NH, Jeong JW. 12-month follow-up results of high dose rosuvastatin loading before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol 2011;146:68-72.
10. Di Sciascio G, Patti G, Pasceri V, Gasparone A, Colonna G, Montinaro A. Efficacy of atorvastatin reloa in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMY-DA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol 2009;54:558-65.
11. Kim JS, Kim J, Choi D, et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. JACC Cardiovasc Interv 2010;3:332-9.
12. van ’t Hof AW, Liem A, Suryapranata H, Hoornije JC, de Boer MJ, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation 1998;97:2302-6.
13. Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996;93:879-88.
14. Levy EI, Kornowski R, Vakin-Assa H, et al. Effect of previous treatment with statins on outcome of patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol 2009;103:165-9.
15. Yun KH, Shin IS, Shin SN, et al. Effect of previous statin therapy in patients with acute coronary syndrome and percutaneous coronary intervention. Korean Circ J 2011;41:458-63.
16. Hahn JY, Kim HJ, Choi YJ, et al. Effects of atorvastatin pretreatment on infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J 2011;162:1026-33.
17. Liu HL, Yang Y, Yang SL, et al. Administration of a loading dose of atorvastatin before percutaneous coronary intervention prevents inflammation and reduces myocardial injury in STEMI patients: a randomized clinical study. Clin Ther 2013;35:261-72.
18. Sposito AC, Chapman MJ. Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol 2002;22:1524-34.
19. Lee CW, Park CS, Hwang J, et al. Expression of HMG-CoA reductase in human coronary atherosclerotic plaques and relationship to plaque destabilisation. Heart 2011;97:715-20.
20. McIntaggart F. Comparative pharmacology of rosuvastatin. Atheroscler Suppl 2003;4:9-14.